Quantcast

Latest Natalizumab Stories

2006-04-07 01:44:27

DUBLIN (Reuters) - Elan Corporation Plc said on Friday the latest trials of its multiple sclerosis drug Tysabri on sufferers showed significant positive effects on their quality of life.

2006-03-29 20:41:12

CHICAGO (Reuters) - Biogen Idec and Elan Corp said on Wednesday they have restarted a safety trial of its multiple sclerosis drug Tysabri, which the drugmakers recalled from the market after reports of rare brain infection were linked to the drug. A U.S.

2006-03-24 17:12:52

WASHINGTON (Reuters) - A review of Biogen Idec and Elan's bid to return multiple sclerosis drug Tysabri to the market "continues to be a high priority," the Food and Drug Administration said on Friday. The FDA had delayed a decision for 90 days, the companies said on Wednesday.

2006-03-08 15:07:29

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - A panel of independent experts on Wednesday unanimously urged the U.S. return of Biogen Idec's multiple sclerosis drug Tysabri, a medicine abruptly pulled from the market last year after it was linked to a life-threatening side effect.

2006-03-08 13:36:22

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Biogen Idec's multiple sclerosis drug Tysabri can return to the market as long as there are safeguards to closely monitor patients for a life-threatening side effect, a U.S. advisory panel unanimously said on Wednesday.

2006-03-08 11:45:00

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan Corp.'s Tysabri multiple sclerosis drug should return to the U.S. market, an advisory panel recommended on Wednesday. Tysabri sales were suspended in February 2005 after three patients developed a serious brain and spinal cord infection.

2006-03-08 12:35:00

Biogen Idec's multiple sclerosis drug Tysabri should return to the market with safeguards to closely monitor patients for a potentially fatal complication, a U.S. advisory panel unanimously ruled on Wednesday.

2006-03-08 11:55:00

By Lisa Richwine GAITHERSBURG, Maryland (Reuters) - Biogen Idec's multiple sclerosis drug Tysabri should return to the market with safeguards to closely monitor patients for a potentially fatal complication, a U.S. advisory panel unanimously ruled on Wednesday.

2006-03-08 10:59:41

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday.

2006-03-08 10:50:18

GAITHERSBURG, Maryland (Reuters) - Biogen Idec and Elan's multiple sclerosis drug Tysabri could be used as a first-choice treatment for some patients if it returns to the market, a U.S. advisory panel said on Wednesday.


Word of the Day
edulcoration
  • The act of sweetening by admixture of some saccharine substance.
The word 'edulcoration' comes from a Latin word meaning 'making sweet'.